Commission must reconsider GSK's dual pricing system, says ECJ
This article was originally published in Scrip
Executive Summary
The European Commission must look again at whether GlaxoSmithKline's dual pricing system in Spain can be exempted from EC competition rules, the European Court of Justice (ECJ) has said.